Handling work for banks as underwriters, O'Melveny has continued to forge a particularly impressive furrow advising China-based technology and life sciences/healthcare companies seeking to list on the HKSE and in the US. Key to the firm’s success in the area is the work of dual New York and Hong Kong-qualified partner Ke Zhu whose biochemistry phD ensures he is able to provide added insight on deals in the sector, including a large proportion of the 18A listings in Hong Kong. Zhu is noted for his ‘solutions-oriented approach’, which also ensures that he is appreciated by clients seeking to execute “first-of-kind” transactions, including his recent work alongside PRC and US practitioners for life sciences company Adlai Nortye, the first US IPO of a China-originated company since the CSRC adopted new measures. Beijing-based Ke Geng co-heads the team alongside Zhu.
Testimonials
Collated independently by Legal 500 research team.
‘Ke Zhu has rich project experience and excels in solving complex problems with a solutions-oriented approach. He works conscientiously and efficiently, and has outstanding professional ability and good communication skills.'
Key clients
- FOLANGSI CO.
- Beijing UBOX Online Technology Corp.
Work highlights
- Represented Tian Tu Capital in its approximately HK$1.13bn IPO and listing of H shares in Hong Kong, the first-ever listing of a PRC VC firm on the Main Board of the Hong Kong Stock Exchange.
- Represented Adlai Nortye in its IPO on the Nasdaq, the first US IPO of a China-originated company since the China Securities Regulatory Commission (CSRC) adopted new measures.